CIRM Funded Clinical Trials

A Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus

Disease Area:

Lupus, Systemic Lupus Erythematosus (SLE)

Investigator:

Barbara Hickingbottom

Institution:

Fate Therapeutics, Inc.

CIRM Grant:

CLIN2-16303 (Pre-Active)

Award Value:

$7,934,448.00

Trial Sponsor:

Fate Therapeutics, Inc.

Trial Stage:

Phase 1

Trial Status:

Launching

Targeted Enrollment:

N/A